Results 31 to 40 of about 128,340 (326)
Prevalence of Hepatitis B in Random Bulgarian Blood Samples – A Single-Site Experience
Acta Medica Bulgarica, 2023 The worldwide distribution of the HBV infection has usually been estimated by the prevalence of hepatitis B surface antigen (HBsAg) among the general population.
Gotseva A., Naseva E.
doaj +1 more source
Journal of Viral Hepatitis, Volume 30, Issue 1, Page 19-28, January 2023., 2023 Abstract ATI‐2173 is an active site polymerase inhibitor nucleotide in development as part of a potentially curative regimen for chronic hepatitis B virus (HBV) infection. This study evaluated the safety, tolerability, pharmacokinetics (PK) and antiviral activity of ATI‐2173.
Katherine E. Squires +9 more
wiley +1 more source
Journal of Viral Hepatitis, Volume 30, Issue 1, Page 73-78, January 2023., 2023 Abstract Chronic hepatitis C virus (HCV) is common. Treatment with direct acting antivirals (DAA) result in high sustained virologic response (SVR) associated with normalization of alanine aminotransferase (ALT). However, abnormal ALT after SVR has been observed.
Nikita Chadha +2 more
wiley +1 more source
Journal of Clinical and Translational Hepatology, 2018 Background and Aims: Hepatitis B surface antigen (HBsAg) loss is seldom achieved with nucleos(t)ide analog (NA) therapy in chronic hepatitis B patients but may be enhanced by switching to finite pegylated-interferon (Peg-IFN) alfa-2a.
P. Hu +26 more
semanticscholar +1 more source
Journal of Viral Hepatitis, Volume 30, Issue 1, Page 4-18, January 2023., 2023 Abstract Hepatitis B, caused by the hepatitis B virus (HBV), is a global public health issue that affects 290 million people worldwide. Most people with hepatitis B are in low‐ and middle‐income countries (LMIC), where health systems and resources are often constrained.
Caroline Lee +2 more
wiley +1 more source
Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now [PDF]
, 2015 Despite of the progress made in vaccine and antiviral therapy development, hepatitis B virus (HBV) infection remains a major health care problem. More than 240 million people are chronically infected worldwide showing differences in the severity of liver
Cuestas, María Luján +4 more
core +1 more source
Prediction of HBF-0259 interactions with hepatitis B Virus receptors and surface antigen secretory factors [PDF]
, 2016 Hepatitis B virus (HBV) is an etiological agent of viral hepatitis, which may lead to cirrhosis, and hepatocellular carcinoma. Current treatment strategies have not shown promising effect to date but various complications such as, drug toxicity ...
Memarian, A., Mohammadi, S., Mohebbi, A.
core +1 more source
Prevalence of Hepatitis B and C Infection Among Street Children Community in Malang City
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy, 2020 Background: World Health Organization (WHO) announced that during 2017, 325 million people worldwide were infected with the hepatitis B virus (HBV) or hepatitis C virus (HCV).
Syifa Mustika, Charisma Dian Simatupang
doaj +1 more source
External quality assessment for dual detection of HBsAg and anti-HCV in serum [PDF]
Pharmaceutical Sciences Asia, 2022 Hepatitis B surface Antigen (HBsAg) and hepatitis C antibody (anti-HCV) assays have been performed in most laboratories using a variety of analytical methods with different reagents for Hepatitis B virus (HBV) and Hepatitis C virus (HCV) screening1-2 ...
Nguyen Thi Minh Thuan +3 more
doaj +1 more source
Frontiers in Immunology, 2019 Development of effective malaria vaccines requires delivery platforms to enhance the immunogenicity and efficacy of the target antigens. This is particularly challenging for transmission-blocking malaria vaccines (TBVs), and specifically for those based ...
A. Marini +10 more
semanticscholar +1 more source